Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Raffaella Di Napoli
Observed name:
Di Napoli, Raffaella
Institutions:
University of Campania "Luigi Vanvitelli",
Regione Campania
Observed institutions:
Université de Bordeaux,
Inserm,
University of Campania "Luigi Vanvitelli",
Regione Campania,
Bordeaux Population Health,
Policlinico Tor Vergata
show all 6
ORCID:
0009-0009-4497-3836
Observed ORCID:
0009-0009-4497-3836
OpenAlex ID:
A5087503582
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
2022
·
Annamaria Mascolo
, Raffaella Di Napoli
, et al.
·
Frontiers in Cardiovascular Medicine
·
109
PDF
Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years
2023
·
Rosanna Ruggiero
, Nunzia Balzano
, et al.
·
Frontiers in Immunology
·
29
PDF
What Is the Role of Nutraceutical Products in Cancer Patients? A Systematic Review of Randomized Clinical Trials
2023
·
Raffaella Di Napoli
, Nunzia Balzano
, et al.
·
Nutrients
·
26
PDF
Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance
2022
·
Rosanna Ruggiero
, Nunzia Balzano
, et al.
·
Frontiers in Immunology
·
25
PDF
Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management
2023
·
Rosanna Ruggiero
, Raffaella Di Napoli
, et al.
·
Expert Review of Clinical Pharmacology
·
23
Happy Air®, a Successful School-Based Asthma Educational and Interventional Program for Primary School Children
2011
·
Loredana Chini
, Roberta Iannini
, et al.
·
Journal of Asthma
·
20
Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data
2022
·
Rosanna Ruggiero
, Barbara Stelitano
, et al.
·
Frontiers in Oncology
·
19
Epigenetic Modifications as Novel Biomarkers for Diagnosis, Prognosis, and Therapeutic Targeting in Thyroid, Pancreas, and Lung Neuroendocrine Tumors
2025
·
Federica Colapietra
, Paola Della Monica
, et al.
·
Journal of Clinical Medicine
·
15
PDF
Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data
2025
·
Nunzia Balzano
, Raffaella Di Napoli
, et al.
·
Pharmacological Reports
·
15
PDF
Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database
2023
·
Liberata Sportiello
, Raffaella Di Napoli
, et al.
·
Pharmaceuticals
·
14
PDF
Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database
2025
·
Raffaella Di Napoli
, Christophe Richez
, et al.
·
Drug Safety
·
12
T-cell malignancies following CAR T-Cell therapy: insights from the FDA Adverse Event Reporting System (FAERS)
2024
·
Raffaella Di Napoli
, Nunzia Balzano
, et al.
·
Expert Opinion on Drug Safety
·
7
Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
2023
·
Annamaria Mascolo
, Raffaella Di Napoli
, et al.
·
Frontiers in Pharmacology
·
4
PDF
Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database
2025
·
Raffaella Di Napoli
, Nunzia Balzano
, et al.
·
Expert Opinion on Drug Safety
·
3
A Long-Term Vision for Rural Areas: The Two Italies
2025
·
Raffaella Di Napoli
, Davide Piacentino
, et al.
·
Nova Science Publishers (Nova Science Publishers, Inc.)
·
3
Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database
2025
·
Raffaella Di Napoli
, Christophe Richez
, et al.
·
Drug Safety
·
2
PDF
Utilizing clinical pharmacology in the drug repurposing arena: a look into COVID-19
2022
·
Rosanna Ruggiero
, Nunzia Balzano
, et al.
·
Expert Review of Clinical Pharmacology
·
2
Adverse event reporting patterns of selective serotonin reuptake inhibitors (SSRIs): disproportionality analysis using the European spontaneous reporting system
2026
·
Ludovica Vittoria Laino
, Annamaria Mascolo
, et al.
·
European Archives of Psychiatry and Clinical Neuroscience
·
1
PDF
Safety profile of fentanyl with different routes of administration: a disproportionality analysis using the EudraVigilance database
2026
·
Raffaella Di Napoli
, Annamaria Mascolo
, et al.
·
Naunyn-Schmiedeberg s Archives of Pharmacology
·
1
PDF
Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database
2025
·
Raffaella Di Napoli
, Christophe Richez
, et al.
·
Drug Safety
·
1
PDF
Hepatobiliary disorders and Direct-Acting Antiviral (DAA) therapies: real-world evidence and insights from the EudraVigilance database
2025
·
John Scicluna
, Raffaella Di Napoli
, et al.
·
Expert Opinion on Drug Safety
·
1
Is teriparatide linked to osteosarcoma? A disproportionality analysis of the FAERS database
2026
·
Nunzia Balzano
, Raffaella Di Napoli
, et al.
·
Pharmacological Reports
PDF
Hepatic Safety Profile of Atomoxetine and Methylphenidate in Patients with ADHD: Disproportionality Analysis Using EudraVigilance Database Data
2026
·
Raffaella Di Napoli
, Ludovica Vittoria Laino
, et al.
·
Pharmaceuticals
PDF
Risk of Rhabdomyolysis Associated with Dexmedetomidine Use over the Past 10 Years: Insights from the EudraVigilance Database
2024
·
Nunzia Balzano
, Annamaria Mascolo
, et al.
·
Journal of Personalized Medicine
PDF
Show more works
View as search
Works count:
26
Citation count:
332
H-index:
11
I10-index:
11
Year
Topic
Type